相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-kappa B activation
Takanori Shinjo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats
Ying Cai et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
Julio Rosenstock et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
Silke Retlich et al.
CLINICAL PHARMACOKINETICS (2015)
Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study
Thomas Forst et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
Nikolaus Marx et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
Lawrence A. Leiter et al.
DIABETES CARE (2015)
Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial
A. Ram Hong et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality-A retrospective nationwide study
Ulrik Madvig Mogensen et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Gillian M. Keating
DRUGS (2015)
Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study
Kazutaka Aoki et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies
Takashi Kadowaki et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits
Toshihiko Yamamoto et al.
HEART RHYTHM (2015)
Relative bioavailability study of linagliptin/metformin tablets in healthy Chinese subjects
Solen Pichereau et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2015)
Cardiovascular Risk Associated With Acarbose Versus Metformin as the First-Line Treatment in Patients With Type 2 Diabetes: A Nationwide Cohort Study
Chia-Hsuin Chang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study
Yuhao Huang et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2015)
Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions
Yukihisa S. Watanabe et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2015)
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad et al.
LANCET (2015)
DPP-4 inhibitors and risk of heart failure EXAMINEd
Eberhard Standl et al.
LANCET (2015)
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
Richard E. Gilbert et al.
LANCET (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Dipeptidyl-Peptidase-4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low-Density Lipoprotein (LDL) Receptor- Deficient Mice
Koji Akita et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A Me Too'' or the Special One'' Antidiabetic Class?
Ricardo Godinho et al.
JOURNAL OF DIABETES RESEARCH (2015)
Efficacy and Safety of a Single-Pill Combination of Vildagliptin and Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial
Masato Odawara et al.
DIABETES THERAPY (2015)
Efficacy and Safety of a Single-Pill Combination of Vildagliptin and Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial
Masato Odawara et al.
DIABETES THERAPY (2015)
DPP-4 inhibitors: a patent review (2012-2014)
Roberto Costante et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2015)
Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan
Szu-Heng Wang et al.
PLOS ONE (2015)
Alogliptin benzoate for management of type 2 diabetes
Yoshifumi Saisho
VASCULAR HEALTH AND RISK MANAGEMENT (2015)
The effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetes
Hirokazu Kakuda et al.
ENDOCRINE (2015)
Myocardial protection by remote ischaemic pre- conditioning is abolished in sulphonylurea- treated diabetics undergoing coronary revascularisation
E. Kottenberg et al.
ACTA ANAESTHESIOLOGICA SCANDINAVICA (2014)
Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus
Uche Anadu Ndefo et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2014)
Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2
Nina Wronkowitz et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2014)
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
Nayyar Iqbal et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats
Toru Miyoshi et al.
CARDIOVASCULAR DIABETOLOGY (2014)
A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study
Toshiyuki Hibuse et al.
CARDIOVASCULAR DIABETOLOGY (2014)
DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure
Nobutaka Koibuchi et al.
CARDIOVASCULAR DIABETOLOGY (2014)
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study
Kazufumi Nakamura et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Yuichi Terawaki et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Bernard Zinman et al.
CARDIOVASCULAR DIABETOLOGY (2014)
On the potential of acarbose to reduce cardiovascular disease
Eberhard Standl et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Charles Pyke et al.
ENDOCRINOLOGY (2014)
Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo
Eunsoo Jung et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors
Theodosios D. Filippatos et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Gliptins-do they increase cardiovascular risk or benefit?
Sheila A. Doggrell et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Sitagliptin and the risk of hospitalization for heart failure: A population-based study
Kang-Ling Wang et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Vildagliptin Stimulates Endothelial Cell Network Formation and Ischemia-induced Revascularization via an Endothelial Nitric-oxide Synthase-dependent Mechanism
Masakazu Ishii et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes
Tesfaye Biftu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison
Paul Craddy et al.
DIABETES THERAPY (2014)
Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
Courtney I. Jarvis et al.
ANNALS OF PHARMACOTHERAPY (2013)
Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes
Katsutoshi Miyagawa et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)
Eyal Leibovitz et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Samuel S. Engel et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report
Yoko Noda et al.
CARDIOVASCULAR DIABETOLOGY (2013)
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
Diethelm Tschoepe et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials
Maximilian von Eynatten et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study
Christine Berndt-Zipfel et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia
Daisuke Kitano et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort Study
Chien-Jung Lu et al.
CEREBROVASCULAR DISEASES (2013)
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
Julio Rosenstock et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment A 1-year, randomized, double-blind, placebo-controlled study
Janet B. McGill et al.
DIABETES CARE (2013)
Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
Per-Henrik Groop et al.
DIABETES CARE (2013)
Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice
Nasib Ervinna et al.
ENDOCRINOLOGY (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes
Yoshimasa Aso et al.
TRANSLATIONAL RESEARCH (2013)
Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans
Shinji Furuta et al.
XENOBIOTICA (2013)
Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
Erika Paniago Guedes et al.
DIABETOLOGY & METABOLIC SYNDROME (2013)
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
Baptist Gallwitz
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2013)
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
Miyako Kishimoto
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2013)
Sitagliptin-Associated Angioedema
A. R. Gosmanov et al.
DIABETES CARE (2012)
Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial
T. Eto et al.
DIABETES OBESITY & METABOLISM (2012)
Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people
Yasushi Kirino et al.
ENDOCRINE JOURNAL (2012)
Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening
Cui Li et al.
JOURNAL OF MOLECULAR MODELING (2012)
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome
William B. White et al.
AMERICAN HEART JOURNAL (2011)
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Daniela Lamers et al.
DIABETES (2011)
Therapy in the Early Stage: Incretins
Simona Cernea et al.
DIABETES CARE (2011)
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
C. F. Deacon
DIABETES OBESITY & METABOLISM (2011)
Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin
U. Graefe-Mody et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data
Arlene M. Gallagher et al.
PLOS ONE (2011)
Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus
Kristian B. Filion et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Dipeptidylpeptitase-4 Inhibitors (Gliptins) Focus on Drug-Drug Interactions
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2010)
Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial
H. M. R. Pattzi et al.
DIABETES OBESITY & METABOLISM (2010)
DPP-4 inhibitors: What may be the clinical differentiators?
John Gerich
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2010)
Lactic Acidosis Induced by Metformin Incidence, Management and Prevention
Jean-Daniel Lalau
DRUG SAFETY (2010)
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes
Yan-Ling He et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue
K. Kos et al.
DIABETES OBESITY & METABOLISM (2009)
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Richard E. Pratley
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
Nancy J. Brown et al.
HYPERTENSION (2009)
Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants
Aziz Karim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Roger Yazbeck et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
Goutam C. Mistry et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Synthesis and structure-activity relationships of potent 1-(2-substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors
Hiroshi Fukushima et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2008)
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptino: A randomized, double-mind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
Paul Covington et al.
CLINICAL THERAPEUTICS (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
The physiology and pharmacology of incretins in type 2 diabetes mellitus
Jens J. Holst
DIABETES OBESITY & METABOLISM (2008)
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
Leo Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule
Adriana Castello Costa Girardi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass
Katarina Kos et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management
G. Crepaldi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2007)
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes - Preclinical biology and mechanisms of action
Daniel J. Drucker
DIABETES CARE (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
G. A. Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Design and synthesis of long-acting inhibitors of dipeptidyl peptidase IV
Takashi Kondo et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans
Stella H. Vincent et al.
DRUG METABOLISM AND DISPOSITION (2007)
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects
Goutam C. Mistry et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers
Yan-Ling He et al.
CLINICAL PHARMACOKINETICS (2007)
11 years of cyanopyrrolidines as DPP-IV inhibitors
Jens-Uwe Peters
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
Gary A. Herman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
Adiponectin and adiponectin receptors
T Kadowaki et al.
ENDOCRINE REVIEWS (2005)
Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors
T Hansotia et al.
DIABETES (2004)
Evidence for an interaction between leptin, T cell costimulatory antigens CD28, CTLA-4 and CD26 (dipeptidyl peptidase IV) in BCG-induced immune responses of leptin- and leptin receptor-deficient mice
J Rüter et al.
BIOLOGICAL CHEMISTRY (2004)
GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine
K Mortensen et al.
REGULATORY PEPTIDES (2003)
Human CD26 expression in transgenic mice affects murine T-cell populations and modifies their subset distribution
L Simeoni et al.
HUMAN IMMUNOLOGY (2002)
Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes
MA Luque et al.
JOURNAL OF ENDOCRINOLOGY (2002)
Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats
JA Pospisilik et al.
DIABETES (2002)
Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
H Ikushima et al.
CELLULAR IMMUNOLOGY (2002)
Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up
EZ Fisman et al.
CLINICAL CARDIOLOGY (2001)
Increased mortality in Type I diabetic patients using sulphonylurea and metformin in combination:: a population-based observational study
J Olsson et al.
DIABETOLOGIA (2000)
分享论文
